MONTE ROSA THERAPEUTICS INC (GLUE) Stock Price & Overview
NASDAQ:GLUE • US61225M1027
Current stock price
The current stock price of GLUE is 17.58 USD. Today GLUE is up by 0.17%. In the past month the price increased by 9.55%. In the past year, price increased by 285.71%.
GLUE Key Statistics
- Market Cap
- 1.407B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.48
- Dividend Yield
- N/A
GLUE Stock Performance
GLUE Stock Chart
GLUE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to GLUE. When comparing the yearly performance of all stocks, GLUE is one of the better performing stocks in the market, outperforming 97.16% of all stocks.
GLUE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GLUE. GLUE has a great financial health rating, but its profitability evaluates not so good.
GLUE Earnings
On March 17, 2026 GLUE reported an EPS of -0.56 and a revenue of 2.78M. The company missed EPS expectations (-56.16% surprise) and missed revenue expectations (-82.42% surprise).
GLUE Forecast & Estimates
15 analysts have analysed GLUE and the average price target is 30.6 USD. This implies a price increase of 74.06% is expected in the next year compared to the current price of 17.58.
For the next year, analysts expect an EPS growth of -250.2% and a revenue growth -58.39% for GLUE
GLUE Groups
Sector & Classification
GLUE Financial Highlights
Over the last trailing twelve months GLUE reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS increased by 52.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.61% | ||
| ROE | -16.57% | ||
| Debt/Equity | 0 |
GLUE Ownership
GLUE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.91 | 365.196B | ||
| AMGN | AMGEN INC | 15.28 | 188.577B | ||
| GILD | GILEAD SCIENCES INC | 15.82 | 172.567B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.61 | 111.931B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.916B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.12 | 44.163B | ||
| INSM | INSMED INC | N/A | 32.624B | ||
| NTRA | NATERA INC | N/A | 28.615B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.011B | ||
| BIIB | BIOGEN INC | 11.08 | 25.883B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.74 | 25.318B | ||
| MRNA | MODERNA INC | N/A | 20.099B | ||
| INCY | INCYTE CORP | 12.6 | 19.015B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GLUE
Company Profile
Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company is headquartered in Boston, Massachusetts. The company went IPO on 2021-06-24. The firm is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Company Info
IPO: 2021-06-24
MONTE ROSA THERAPEUTICS INC
321 Harrison Avenue, Suite 900
Boston MASSACHUSETTS US
CEO: Markus Warmuth
Employees: 147
Phone: 16179492643
MONTE ROSA THERAPEUTICS INC / GLUE FAQ
Can you describe the business of MONTE ROSA THERAPEUTICS INC?
Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company is headquartered in Boston, Massachusetts. The company went IPO on 2021-06-24. The firm is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
What is the stock price of MONTE ROSA THERAPEUTICS INC today?
The current stock price of GLUE is 17.58 USD. The price increased by 0.17% in the last trading session.
Does MONTE ROSA THERAPEUTICS INC pay dividends?
GLUE does not pay a dividend.
What is the ChartMill rating of MONTE ROSA THERAPEUTICS INC stock?
GLUE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists GLUE stock?
GLUE stock is listed on the Nasdaq exchange.
Is MONTE ROSA THERAPEUTICS INC (GLUE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GLUE.
What is the employee count for GLUE stock?
MONTE ROSA THERAPEUTICS INC (GLUE) currently has 147 employees.